Results 151 to 160 of about 3,877 (197)

Interpreting Rituximab Response in Seronegative Membranous Nephropathy [Response to Letter]. [PDF]

Drug Des Devel Ther
Yang Y, Xie X, Xu G.
europepmc   +1 more source

Anti-PLA2R antibodies: implications for therapeutic planning and the prediction of remission in membranous nephropathy. [PDF]

J Bras Nefrol
Mastroianni-Kirsztajn G, Riguetti MTP, Siliano JM.   +2 more
europepmc   +1 more source

Key Points in Managing PLA2R-Associated Membranous Nephropathy

Kidney International Reports
Raja Ramachandran, Vivekanand Jha, Bhadran Bose   +2 more
openaire   +5 more sources

Liver-kidney crosstalk in primary biliary cholangitis: insights into the mechanisms of renal involvement. [PDF]

Front Immunol
Fan Z, Jia S, Wei Y, Fan X, Li X, Wang L.   +5 more
europepmc   +1 more source

Efficacy and safety of obinutuzumab in refractory membranous nephropathy: a single-arm meta-analysis. [PDF]

Front Immunol
Cong P, Wang J, Du X.
europepmc   +1 more source

A comparative study on the efficacy of rituximab combined with tacrolimus and methylprednisolone in the treatment of patients with moderate-high risk idiopathic membranous nephropathy. [PDF]

Am J Transl Res
Li W, Wang Z, Xiao Z.
europepmc   +1 more source

Delayed but durable remission to rituximab in PLA2R-associated membranous nephropathy despite B-cell reconstitution: a case report. [PDF]

BMC Nephrol
Yang R, Zhu H, Luo Z, He T, Jiang M, Zhang Y, Wang T.   +6 more
europepmc   +1 more source

Obinutuzumab after anti-rituximab antibody-associated treatment failure in membranous nephropathy: a case report. [PDF]

Front Immunol
Guo J, Zhong A, Wu D, Liu Y, Chen Y, Xu Y, Xu R, Wan Q.   +7 more
europepmc   +1 more source